Plo, Isabelle

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment

Cited by 1,776

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell

Acute Myeloid Leukemia ResearchChromatin Remodeling and Cancer

Cited by 924

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

Rodriguez-Meira, A., Norfo, R., Wen, S., Chédeville, A. L., Rahman, H., O’Sullivan, J., Wang, G., Louka, E., Kretzschmar, W. W., Paterson, A., et al. (2023) · Nature Genetics

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 158

Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms

Mosca, M., Hermange, G., Tisserand, A., Noble, R., Marzac, C., Marty, C., Le Sueur, C., Campario, H., Vertenoeil, G., El-Khoury, M., et al. (2021) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 57

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis

Mahfoudhi, E., Lordier, L., Marty, C., Pan, J., Roy, A., Roy, L., Rameau, P., Abbes, S., Debili, N., Raslova, H., et al. (2016) · Oncotarget

Platelet Disorders and TreatmentsCancer-related Molecular Pathways

Cited by 53